Results 201 to 210 of about 31,009,639 (254)

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

Clinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke, Boitumelo Semete‐Makokotlela, Varnika Singh, Khanyisile Nkuku, Madelein Terblanche, Ezekiel T Mukanga, Nancy Ngum, Kudakwashe Dandajena, McNeil Chimus Mhango, Paulyne Wairimu, John Mwangi, Dominique Lagrave, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

Old data, new tricks: Comprehensive computational analysis of 10 years of multi‐center EuroFlow acute myeloid leukemia diagnostic immunophenotypic data

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight centers over a period of 10 
Sarah Bonte, Rosan Olsman, Sofie Van Gassen, Sergio Matarraz, Neus Villamor, Stefan Nierkens, Paula Fernandez, Elaine Sobral da Costa, Carmen‐Mariana Aanei, Alberto Orfao, Jacques J. M. van Dongen, Yvan Saeys, Mattias Hofmans, Vincent H. J. van der Velden   +13 more
wiley   +1 more source

Regulation of neutrophil extracellular trap formation by c-di-GMP in <i>Pseudomonas aeruginosa</i>-induced pleural infection. [PDF]

Front Immunol
Qing C, Huang W, Shi L, Luo J, Zheng S, Kong J, Wang K.   +6 more
europepmc   +1 more source

Clinical applications of CD34+ progenitor cell immunophenotyping in myelodysplastic neoplasms—The CytHem SMD French network experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a risk of progression to acute myeloid leukemia. As the disease originates in hematopoietic stem and progenitor cells (HSPCs), flow cytometry (FCM) has emerged as a key approach to interrogate the bone ...
Nicolas Chapuis, Anne‐Catherine Lhoumeau, Stéphanie Mathis, Michel Ticchioni, Valérie Bardet, the French Working Group CytHem‐SMD   +5 more
wiley   +1 more source

Distinct PlzC mechanisms integrate chemotaxis and c-di-GMP signaling to regulate <i>Vibrio cholerae</i> motility and biofilm formation. [PDF]

Proc Natl Acad Sci U S A
Park JH, Kennedy EN, Tripathi S, Romp AB, Rubin SM, Bourret RB, Yildiz FH.   +6 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Ampicillin promotes the biofilm formation of <i>Shewanella putrefaciens</i> through the c-di-GMP-regulated BpfAGD system. [PDF]

Microbiol Spectr
Shi R, Sun D, Liu J, Yang J, Zhu J, Liu C, Liu W.   +6 more
europepmc   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Parallel regulatory circuits orchestrate biofilm formation in response to c-di-GMP levels and growth phase. [PDF]

PLoS Genet
Trebino MA, Kitts G, Haycocks JRJ, Wheat R, Chaudry I, Park JH, Erill I, Grainger DC, Yildiz FH.   +8 more
europepmc   +1 more source